Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

By comparing patients with and without VC, the history of calcium carbonate or vitamin D supplementation showed no statistical difference (p > 0.05), whereas sex, smoking status, alcohol consumption, history of underlying diseases (hypertension, diabetes, chronic heart disease, hyperlipidemia), CKD stage, and cause of CKD were significantly associated with VC (p < 0.05).

Source: Comparison of clinical characteristics and laboratory indexes consisting of C3 and C4 levels in the group with and without VC. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cross-sectional study.

Cross-sectional study

Examines a population at a particular point in time.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Correlation between complement C3 level and abdominal aortic calcification in non-dialysis chronic kidney disease patients: a cross-sectional study

Source: Article title.

Four hundred and fifty six NDD-CKD patients were enrolled from 2019 to 2022.

Source: Abstract.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Full studies

Correlation between complement C3 level and abdominal aortic calcification in non-dialysis chronic kidney disease patients: a cross-sectional study

Cross-sectional study · Frontiers in Medicine · 2026

Original publication title

Correlation between complement C3 level and abdominal aortic calcification in non-dialysis chronic kidney disease patients: a cross-sectional study

Chenfei Fu; Wen Li; Weijia Xu; Xinmei Huang; Wenqiong Cao; Aihua Zhang

Copyright © 2026 Fu, Li, Xu, Huang, Cao and Zhang.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

In patients with NDD-CKD, serum complement C3 exhibits a J-shaped relationship with vascular calcification, indicating a complex, non-linear association. Additionally, older age, hypertension, and hyperlipidemia were confirmed as independent risk factors.

An extract from the source publication. Read it in context.

At a glance

Study background

What background does the paper provide?

Cardiovascular events represent the primary determinant of poor prognosis in patients with CKD (1 to 4). VC, highly prevalent in CKD populations, strongly predicts cardiovascular mortality (5 to 7). Despite the established significance of VC, the clinical tools for its robust evaluation in routine practice remain suboptimal. Traditional biomarkers, such as serum calcium, phosphate, and parathyroid hormone (PTH), have been extensively studied. However, their predictive performance for VC has consistently been modest and inconsistent across studies. Moreover, other novel biomarkers, such as fibroblast growth factor-23 (FGF-23) and klotho, while mechanistically involved, have yet to demonstrate sufficient prognostic value or cost-effectiveness to be adopted into widespread clinical practice (8, 9).

Recent studies have shown that complement activation is associated with many diseases and their complications (10). Nagaraj et al. (11) reported a significant correlation between higher C3 levels and the presence and severity of arterial calcification in healthy midlife women. Extending this concept to metabolic disease, Copenhaver et al. (12) demonstrated that elevated C3 and C4 levels in obese youth may serve as early indicators for atherosclerosis risk. Collectively, these findings position complement components as promising biomarkers for cardiovascular risk stratification (13).

This association has been confirmed in hemodialysis-dependent CKD (HD-CKD) patients, with C3 identified as an independent risk factor for VC (14). Nonetheless, the unique uremic milieu and intensive dialysis regimens in HD patients may confound the specific role of C3. Given the high incidence and progression of VC in NDD-CKD patients (15), reliance on HD data alone is insufficient for understanding this relationship at earlier, more modifiable disease stages. Thus, the utility of C3 as a VC biomarker in NDD-CKD patients remains an unaddressed gap.

This study aims to explore the relationship between C3 and VC in NDD-CKD patients, providing novel insights for the targeted precision therapy of VC.

Source: Introduction Source: Introduction

Study methods

What methods does the paper describe?

2.1

Study subjects

This cross-sectional observational study screened 737 NDD-CKD patients at Xuanwu Hospital of Capital Medical University from 2019 to 2022. Our exploration was restricted to subjects over 18 years old (N = 737). A series of sample selection processes were applied according to the exclusion criteria: (1) history of dialysis or kidney transplantation (N = 22); (2) patients with acute renal failure (N = 38); patients with active systemic inflammation or acute infection (N = 20); (3) autoimmune diseases (N = 6); (4) incomplete test for VC (N = 240); (5) missing data on available covariates: C3 (N = 8); C4 (N = 8); serum calcium (N = 13); uric acid (N = 253); 24 urinary protein (N = 46).

Consequently, our study included 456 adult participants with complete information in the final analysis (Figure 1). The participants provided written informed consent before enrollment, and research protocols were approved by the Ethics Committee of Xuanwu Hospital, Capital Medical University [(2019)131].

Figure 1

Flowchart of participants’ selection.

Figure image at the original source: open the original paper. This file is not included in this text import.
2.2

Study methods

Clinical data were collected from 456 NDD-CKD patients, including demographics (gender, age, smoking status, alcohol use), etiology, CKD stage, blood pressure (systolic/diastolic), and medical history (hypertension, diabetes, chronic heart disease, hyperlipidemia, calcium carbonate/vitamin D supplementation). Serum levels of calcium, phosphorus, albumin, hemoglobin, uric acid, total cholesterol, low-density lipoprotein cholesterol (LDL-C), creatinine, and alanine were measured using an automatic biochemical analyzer. The levels of C3 and complement 4 (C4) were quantified via immunoscattering turbidimetry.

2.3

Assessment of vascular calcification

Vascular calcification (VC) was assessed using available chest CT imaging. The thoracic aorta was evaluated. VC was defined as discrete foci of ≥1 mm2 within the aortic wall with an attenuation of >130 Hounsfield units (HU), consistent with established methodologies (16).

Source: Materials and methods Source: Materials and methods Source: Materials and methods

Comparison of clinical characteristics and laboratory indexes consisting of C3 and C4 levels in the group with and without VC

Results: Comparison of clinical characteristics and laboratory indexes consisting of C3 and C4 levels in the group with and without VC

A total of 456 NDD-CKD patients were enrolled, including 233 with VC and 223 without VC. The general situation of the vascular calcification group and the non-vascular calcification group is presented in Table 1. The median age of the patients in the CKD with VC group was 65.00 (58.00 to 72.00) years. The median age of the patients in the CKD without VC group was 53.00 (42.00 to 64.00) years. By comparing patients with and without VC, the history of calcium carbonate or vitamin D supplementation showed no statistical difference (p > 0.05), whereas sex, smoking status, alcohol consumption, history of underlying diseases (hypertension, diabetes, chronic heart disease, hyperlipidemia), CKD stage, and cause of CKD were significantly associated with VC (p < 0.05).

Table 1

Comparison of baseline characteristics between those without VC and the VC groups in NDD-CKD patients.

VariablesCKD without VC group (N = 223)CKD with VC group (N = 233)p-value
Age [M (P25: P75), years]53.00 (42.00 to 64.00)65.00 (58.00 to 72.00)<0.001*
Sex0.007*
Male/[n (%)]128 (57.4%)164 (70.4%)
Female/[n (%)]95 (42.6%)69 (29.6%)
Smoking/[n (%)]90 (40.4%)132 (56.7%)<0.001*
Drinking/[n (%)]60 (26.9%)98 (42.1%)<0.001*
Underlying diseases<0.001*
Hypertension/[n (%)]166 (74.4%)212 (90.9%)
Diabetes/[n (%)]80 (35.9%)152 (65.2%)
CHD/[n (%)]28 (12.6%)73 (31.3%)
Hyperlipidemia/[n (%)]112 (50.2%)156 (67.0%)
History of medications
Calcium carbonate/[n (%)]72 (32.3%)60 (25.8%)0.140
Vitamin D/[n (%)]54 (24.2%)44 (18.9%)0.140
CKD stage<0.001*
CKD1/[n (%)]69 (30.9%)25 (10.7%)
CKD2/[n (%)]34 (15.2%)33 (14.2%)
CKD3/[n (%)]46 (20.6%)82 (35.2%)
CKD4/[n (%)]36 (11.7%)41 (17.6%)
CKD5/[n (%)]38 (17.0%)52 (22.3%)
Etiology of CKD<0.001*
DKD/[n (%)]41 (18.4%)88 (37.8%)
HRD/[n (%)]13 (5.83%)21 (9.01%)
Glomerulonephritis/[n (%)]169 (75.8%)124 (53.2%)
Serum phosphate (mean ± SD, mmol/L)1.29 ± 0.401.34 ± 0.360.019*
Serum calcium (mean ± SD, mmol/L)2.15 ± 0.212.16 ± 0.270.740
BMI (mean ± SD, kg/m2)26.38 ± 4.4426.16 ± 4.310.437
SBP (mean ± SD, mmHg)142.04 ± 21.08146.95 ± 21.170.011*
DBP (mean ± SD, mmHg)86.57 ± 15.2581.91 ± 11.93<0.004*
24urinary protein (mean ± SD, g/24 h)3.12 ± 2.732.95 ± 2.910.247
Creatinine (mean ± SD, μmol)229.37 ± 243.92263.06 ± 275.960.001*
Alanine (mean ± SD, IU/L)22.18 ± 16.5216.82 ± 9.95<0.001*
Cholesterol (mean ± SD, mmol/L)5.17 ± 2.074.64 ± 1.580.005*
Low-density lipoprotein (mean ± SD, mmol/L)3.19 ± 1.722.79 ± 1.200.019*
ALB (mean ± SD, g/L)33.77 ± 7.9733.50 ± 6.630.318
C3 (mean ± SD, g/L)0.91 ± 0.210.86 ± 0.200.011*
C4 (mean ± SD, g/L)0.25 ± 0.080.25 ± 0.080.841
Uric acid [M (P25: P75), μmol/L]401 (319 to 478.5)414 (340 to 501)0.062
Hemoglobin [M (P25: P75), g/L]109 (94.5 to 133)108 (93 to 119)0.015*

Data are shown as mean ± SD or median (interquartile range) for continuous variables and proportions for categorical variables. p < 0.05 is marked with *.

VC, vascular calcification; CKD, chronic kidney disease; CHD, chronic heart disease; HRD, hypertensive renal damage; DKD, diabetic kidney disease; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; ALB, albumin; VC, vascular calcification; CKD, chronic kidney disease; C3, complement 3; C4, complement 4.

The VC group exhibited higher systolic blood pressure, creatinine, and serum phosphate than those in the group without VC (p < 0.05), and lower diastolic blood pressure, cholesterol, low-density lipoprotein cholesterol, and hemoglobin than those in the group without VC (p < 0.05). Serum calcium, body mass index (BMI), 24-h urinary protein, and uric acid did not differ between the two groups (p > 0.05).

When analyzed as continuous variables, C3 showed a significant negative association with VC (p < 0.05), with a monotonic downward trend in the non-VC group, while C4 was not statistically significant.

Source: Comparison of clinical characteristics and laboratory indexes consisting of C3 and C4 levels in the group with and without VC Source: Comparison of clinical characteristics and laboratory indexes consisting of C3 and C4 levels in the group with and without VC Source: Comparison of clinical characteristics and laboratory indexes consisting of C3 and C4 levels in the group with and without VC Source: Comparison of clinical characteristics and laboratory indexes consisting of C3 and C4 levels in the group with and without VC

Correlation between C3 and VC and laboratory indicators

Results: Correlation between C3 and VC and laboratory indicators

Initial Spearman correlation analysis showed that C3 was negatively correlated with VC (r = −0.113, p = 0.015) and positively correlated with hemoglobin, alanine, cholesterol, and low-density lipoprotein cholesterol (ρ = 0.352, 0.264, 0.183, 0.163, p < 0.001) (see Figure 2).

Figure 2

Correlation between plasma C3 and hemoglobin in NDD-CKD patients. NDD-CKD, non-dialysis chronic kidney disease. Correlation between plasma C3 level and hemoglobin in NDD-CKD patients, Spearman’s ρ = 0.18, p < 0.001.

Figure image at the original source: open the original paper. This file is not included in this text import.
Source: Correlation between C3 and VC and laboratory indicators Source: Correlation between C3 and VC and laboratory indicators

Nonlinear association between C3 and traditional VC risk factors

Results: Nonlinear association between C3 and traditional VC risk factors

Given the complex biology of the complement system, we further used restricted cubic spline (RCS) curve analysis to explore possible nonlinear relationships between C3 and VC. The RCS analysis confirmed a J-shaped relationship between C3 and VC (p = 0.045), with an inflection point at 0.83 g/L. Below or above this value, the risk of VC increased (Figure 3).

Figure 3

Nonlinear association between C3 and vascular calcification. VC, vascular calcification. Restricted cubic spline analysis revealed a significant non-linear J-shaped association between C3 levels and vascular calcification risk (p-non-linear <0.001), with overall statistical significance (p-overall = 0.045).

Figure image at the original source: open the original paper. This file is not included in this text import.
Source: Nonlinear association between C3 and traditional VC risk factors Source: Nonlinear association between C3 and traditional VC risk factors

Analysis of influencing factors of VC in NDD-CKD patients

Results: Analysis of influencing factors of VC in NDD-CKD patients

The J-shaped relationship clarifies that the risk of VC is not uniformly related to C3 across its entire range, and the mean value may mask the true relationship. To further investigate this, C3 was divided into three subgroups by tertiles: C3_quartile.L (0.39 to 0.80 g/L), C3_quartile.Q (0.81 to 0.94 g/L), and C3_quartile.C (0.95 to 1.63 g/L). The C3_quartile.Q was set as the baseline because it encompasses the inflection point (0.83 g/L) and thus represents the patient group with the lowest risk.

Seventeen parameters with p < 0.1 in univariate logistic regression were included in multivariate analysis (Figure 4). The high C3 tertile (C) was significantly associated with VC [odds ratio (OR) = 2.06, 95% confidence interval (CI): 1.13 to 3.83, p = 0.020], whereas the low tertile (L) showed no significant association. Despite a lower mean C3 in the VC group, the highest C3 tertile conferred a twofold VC risk (OR = 2.06). This apparent contradiction can be explained by the J-shaped relationship identified in the RCS analysis.

Despite a lower mean C3 in the VC group, the highest C3 tertile conferred a twofold VC risk (OR = 2.06). This apparent contradiction can be explained by the J-shaped relationship identified in the RCS analysis. The J-shaped curve indicates that both low and high levels of C3 are associated with an increased risk of VC, with the lowest risk occurring at an intermediate C3 level (0.81 to 0.94 g/L). Therefore, while the mean C3 level in the VC group is lower, the highest C3 tertile still represents a significant risk factor for VC.

Figure 4

Estimated odds ratios determined in a logistic regression model. OR, odds ratio; CI, confidence interval. Among 17 risk factors, only C3_quartileC, age, hypertension, and hyperlipidemia prevalence had a p-value <0.05.

Figure image at the original source: open the original paper. This file is not included in this text import.

In addition to C3, older age, hypertension, and hyperlipidemia were identified as independent risk factors for VC in NDD-CKD patients.

Source: Analysis of influencing factors of VC in NDD-CKD patients Source: Analysis of influencing factors of VC in NDD-CKD patients Source: Analysis of influencing factors of VC in NDD-CKD patients Source: Analysis of influencing factors of VC in NDD-CKD patients

The predictive value of C3 for VC in NDD-CKD patients

Results: The predictive value of C3 for VC in NDD-CKD patients

The ROC curve was used to analyze the ability of C3 to diagnose vascular calcification, which showed an area under the curve (AUC) of 0.849 (95% confidence interval: 0.814 to 0.884) for C3 in predicting VC, indicating high diagnostic accuracy (Table 2).

Table 2

The predictive value of C3 for VC in NDD-CKD patients.

Cut-offSensitivitySpecificityAccuracyAUCAUC 95% CI
0.5340.7940.7670.7810.8490.849 (0.814 to 0.884)

AUC, area under the curve; CI, confidence interval; C3, complement3; VC, vascular calcification; NDD-CKD, non-dialysis dependent CKD.

Source: The predictive value of C3 for VC in NDD-CKD patients Source: The predictive value of C3 for VC in NDD-CKD patients

Discussion

This study provides the first exploration of the association between C3 and VC in patients with NDD-CKD. Our findings reveal a significant J-shaped relationship (p = 0.045), with an inflection point at 0.83 g/L. This indicates that both low and high C3 levels are associated with an increased risk of VC, revealing a previously unrecognized complexity in their association.

Previous studies have demonstrated that the complement system may play a crucial role in the development of VC (17). A study in subclinical atherosclerosis has identified complement system activation as a hallmark of early plaque formation (18). Complement C3 is the core of the complement system, with the highest serum content in all complement components, and is the intersection hub of complement activation pathways (19). In hemodialysis patients, Wang et al. (14) have demonstrated that C3 acts as a predictor of vascular calcification.

Our study also confirmed the association of C3 and vascular calcification in non-hemodialysis patients. However, unlike the linear relationship between C3 and VC in hemodialysis patients (14), a J-shaped relationship was observed in NDD-CKD patients in our study. This difference may be attributed to complement activation’s involvement in hypersensitivity reactions (such as CARPA) and acute reactions during HD. The uremic environment and recurrent inflammatory stimuli during dialysis may significantly alter C3 metabolism compared to the non-dialysis state (20).

The J-shaped relationship demonstrates that the apparent paradox, a lower mean C3 level in the VC group alongside an elevated risk in the highest C3 tertile, arises because the population mean obscures a high-risk subgroup driven by elevated C3 levels. Similar to bone formation, vascular calcification is a process of ectopic bone formation influenced by factors like abnormal mineral metabolism, uremic toxins, inflammation, and oxidative stress (21, 22). On one hand, complement C3 has a dual role in inducing osteoclast formation (23) and regulating the inflammatory environment, impacting osteoclast differentiation (24).

This enhanced osteoclast activity can lead to bone loss, increasing blood calcium levels, and the risk of soft tissue calcification in vascular walls, which may promote vascular calcification (25, 26). On the other hand, our study showed that low complement C3 levels also caused vascular calcification. The complement system is not only involved in the inflammatory response, but also in the removal of cellular debris and apoptotic cells (10). We propose that low C3 levels may result in impaired clearance of these functions, allowing cell debris and apoptotic cells to accumulate in the vessel wall.

This accumulated cellular debris can act as an inducer of calcification and promote the formation of hydroxyapatite crystals, which can lead to vascular calcification (27). In addition to low C3 levels, an imbalance in complement regulation, potentially caused by excessive activation, could be a significant factor. This idea is supported by the predictive value of the C3d/C3 ratio, which reflects the balance between activation and abundance (28). Studies have shown that deficiencies in regulators like CD59 can worsen vascular disease (29).

To better understand the role of complement dysregulation in vascular calcification, future research should focus on quantifying complement activation fragments and regulators directly. While our study highlights the importance of complement dysregulation, it is essential to recognize that vascular calcification is a complex process involving multiple factors, including the FGF-23: Klotho axis and oxidative stress (30 to 32). Future prospective studies should measure these factors in conjunction with complement components to better understand their interactions and contributions to VC.

Clinically, NDD-CKD patients with VC were significantly older than patients without VC (65 years vs. 53 years), had higher systolic blood pressure, lower diastolic blood pressure, cholesterol, low-density lipoprotein, and hemoglobin, and higher rates of hypertension, diabetes, and hyperlipidemia prevalence (all p < 0.05), showing no difference in calcium/vitamin D supplementation. This is generally consistent with prior studies (33 to 35). Meanwhile, in this study, C3 was found to be positively correlated with hemoglobin, total cholesterol, and LDL-C, markers of inflammatory responses and metabolic disorders (36).

Inflammation and metabolic disorders are important risk factors for VC, suggesting indirect VC promotion via these pathways, while this study did not demonstrate a significant relationship between C4 and VC, aligning with studies in hemodialysis patients. However, Bi et al. (37) identified C4 as a prognostic marker in IgA nephropathy patients. This study did not include prognostic analysis due to the short follow-up time, but future studies should explore the association of plasma C4 levels with cardiovascular disease (CVD) and mortality in NDD-CKD patients.

The impact of C3 activation on vascular calcification (VC) may vary depending on the underlying etiology of kidney disease, as complement dysregulation is a common feature in various glomerulonephritides, including IgA nephropathy, lupus nephritis, APS, and others, as documented in previous studies (38, 39). This diversity in etiology prompted us to stratify our analysis by glomerulonephritis (GN) status. Our analysis demonstrated a significant association between higher C3 levels and an increased risk of VC in the GN subgroup.

However, in the non-GN subgroup, this association did not reach statistical significance, likely due to the limited statistical power of the smaller cohort (approximately 100 patients). Future large-scale, multicenter studies with etiology-specific designs are needed to validate these potential differences and elucidate the underlying pathophysiology.

The ROC curve showed that the AUC of C3 in predicting VC in NDD-CKD patients was 0.849 g/L, indicating a high predictive value. The predictive sensitivity and specificity were 79.4 and 76.7%, respectively. C3 may be an important biomarker for predicting VC in NDD-CKD patients.

In clinical practice, C3 serves as a valuable biomarker for assessing the risk of vascular calcification in patients with NDD-CKD. In patients with markedly altered C3 levels, whether elevated or decreased, especially among the elderly with hypertension and hyperlipidemia, close monitoring for signs of VC (using methods such as X-ray) is essential for the early identification of high-risk individuals. In addition to monitoring, the trend in C3 levels can guide clinical management decisions. Elevated C3 levels, particularly those in the high-normal range, may require closer monitoring, whereas low C3 levels may indicate complement dysregulation or associated comorbidities.

This targeted approach facilitates more precise interventions, ultimately improving patient outcomes.

This study has several limitations that should be considered when interpreting the findings. First, we could only classify vascular calcification as present or absent due to the lack of a standardized grading system for aortic calcification on CT scans. While our method was reliable, it may not fully capture the range of disease severity. Second, a single cross-sectional C3 measurement may not accurately reflect long-term complement dynamics, though we mitigated this by excluding patients with acute comorbidities known to cause transient fluctuations.

Additionally, medication use was documented from medical records, but real-world adherence may not have been fully captured. Finally, as a single-center study, our findings require validation in more diverse populations. Despite these limitations, the consistency and robustness of the primary nonlinear association provide compelling evidence for a complex relationship between C3 and vascular calcification, laying the groundwork for future longitudinal studies with quantitative calcification scoring.

Collectively, these findings deepen our understanding of the possible mechanisms of VC. With the ongoing development of C3-targeted therapies, in the future, C3 may be applied to the clinical treatment of VC in CKD, thereby improving the quality of life for patients and achieving better survival benefits.

Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion

Results

4.1

Comparison of clinical characteristics and laboratory indexes consisting of C3 and C4 levels in the group with and without VC

A total of 456 NDD-CKD patients were enrolled, including 233 with VC and 223 without VC. The general situation of the vascular calcification group and the non-vascular calcification group is presented in Table 1. The median age of the patients in the CKD with VC group was 65.00 (58.00 to 72.00) years. The median age of the patients in the CKD without VC group was 53.00 (42.00 to 64.00) years. By comparing patients with and without VC, the history of calcium carbonate or vitamin D supplementation showed no statistical difference (p > 0.05), whereas sex, smoking status, alcohol consumption, history of underlying diseases (hypertension, diabetes, chronic heart disease, hyperlipidemia), CKD stage, and cause of CKD were significantly associated with VC (p < 0.05).

Table 1

Comparison of baseline characteristics between those without VC and the VC groups in NDD-CKD patients.

VariablesCKD without VC group (N = 223)CKD with VC group (N = 233)p-value
Age [M (P25: P75), years]53.00 (42.00 to 64.00)65.00 (58.00 to 72.00)<0.001*
Sex0.007*
Male/[n (%)]128 (57.4%)164 (70.4%)
Female/[n (%)]95 (42.6%)69 (29.6%)
Smoking/[n (%)]90 (40.4%)132 (56.7%)<0.001*
Drinking/[n (%)]60 (26.9%)98 (42.1%)<0.001*
Underlying diseases<0.001*
Hypertension/[n (%)]166 (74.4%)212 (90.9%)
Diabetes/[n (%)]80 (35.9%)152 (65.2%)
CHD/[n (%)]28 (12.6%)73 (31.3%)
Hyperlipidemia/[n (%)]112 (50.2%)156 (67.0%)
History of medications
Calcium carbonate/[n (%)]72 (32.3%)60 (25.8%)0.140
Vitamin D/[n (%)]54 (24.2%)44 (18.9%)0.140
CKD stage<0.001*
CKD1/[n (%)]69 (30.9%)25 (10.7%)
CKD2/[n (%)]34 (15.2%)33 (14.2%)
CKD3/[n (%)]46 (20.6%)82 (35.2%)
CKD4/[n (%)]36 (11.7%)41 (17.6%)
CKD5/[n (%)]38 (17.0%)52 (22.3%)
Etiology of CKD<0.001*
DKD/[n (%)]41 (18.4%)88 (37.8%)
HRD/[n (%)]13 (5.83%)21 (9.01%)
Glomerulonephritis/[n (%)]169 (75.8%)124 (53.2%)
Serum phosphate (mean ± SD, mmol/L)1.29 ± 0.401.34 ± 0.360.019*
Serum calcium (mean ± SD, mmol/L)2.15 ± 0.212.16 ± 0.270.740
BMI (mean ± SD, kg/m2)26.38 ± 4.4426.16 ± 4.310.437
SBP (mean ± SD, mmHg)142.04 ± 21.08146.95 ± 21.170.011*
DBP (mean ± SD, mmHg)86.57 ± 15.2581.91 ± 11.93<0.004*
24urinary protein (mean ± SD, g/24 h)3.12 ± 2.732.95 ± 2.910.247
Creatinine (mean ± SD, μmol)229.37 ± 243.92263.06 ± 275.960.001*
Alanine (mean ± SD, IU/L)22.18 ± 16.5216.82 ± 9.95<0.001*
Cholesterol (mean ± SD, mmol/L)5.17 ± 2.074.64 ± 1.580.005*
Low-density lipoprotein (mean ± SD, mmol/L)3.19 ± 1.722.79 ± 1.200.019*
ALB (mean ± SD, g/L)33.77 ± 7.9733.50 ± 6.630.318
C3 (mean ± SD, g/L)0.91 ± 0.210.86 ± 0.200.011*
C4 (mean ± SD, g/L)0.25 ± 0.080.25 ± 0.080.841
Uric acid [M (P25: P75), μmol/L]401 (319 to 478.5)414 (340 to 501)0.062
Hemoglobin [M (P25: P75), g/L]109 (94.5 to 133)108 (93 to 119)0.015*

Data are shown as mean ± SD or median (interquartile range) for continuous variables and proportions for categorical variables. p < 0.05 is marked with *.

VC, vascular calcification; CKD, chronic kidney disease; CHD, chronic heart disease; HRD, hypertensive renal damage; DKD, diabetic kidney disease; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; ALB, albumin; VC, vascular calcification; CKD, chronic kidney disease; C3, complement 3; C4, complement 4.

The VC group exhibited higher systolic blood pressure, creatinine, and serum phosphate than those in the group without VC (p < 0.05), and lower diastolic blood pressure, cholesterol, low-density lipoprotein cholesterol, and hemoglobin than those in the group without VC (p < 0.05). Serum calcium, body mass index (BMI), 24-h urinary protein, and uric acid did not differ between the two groups (p > 0.05).

When analyzed as continuous variables, C3 showed a significant negative association with VC (p < 0.05), with a monotonic downward trend in the non-VC group, while C4 was not statistically significant.

4.2

Correlation between C3 and VC and laboratory indicators

Initial Spearman correlation analysis showed that C3 was negatively correlated with VC (r = −0.113, p = 0.015) and positively correlated with hemoglobin, alanine, cholesterol, and low-density lipoprotein cholesterol (ρ = 0.352, 0.264, 0.183, 0.163, p < 0.001) (see Figure 2).

Figure 2

Correlation between plasma C3 and hemoglobin in NDD-CKD patients. NDD-CKD, non-dialysis chronic kidney disease. Correlation between plasma C3 level and hemoglobin in NDD-CKD patients, Spearman’s ρ = 0.18, p < 0.001.

Figure image at the original source: open the original paper. This file is not included in this text import.
4.3

Nonlinear association between C3 and traditional VC risk factors

Given the complex biology of the complement system, we further used restricted cubic spline (RCS) curve analysis to explore possible nonlinear relationships between C3 and VC. The RCS analysis confirmed a J-shaped relationship between C3 and VC (p = 0.045), with an inflection point at 0.83 g/L. Below or above this value, the risk of VC increased (Figure 3).

Figure 3

Nonlinear association between C3 and vascular calcification. VC, vascular calcification. Restricted cubic spline analysis revealed a significant non-linear J-shaped association between C3 levels and vascular calcification risk (p-non-linear <0.001), with overall statistical significance (p-overall = 0.045).

Figure image at the original source: open the original paper. This file is not included in this text import.
4.4

Analysis of influencing factors of VC in NDD-CKD patients

The J-shaped relationship clarifies that the risk of VC is not uniformly related to C3 across its entire range, and the mean value may mask the true relationship. To further investigate this, C3 was divided into three subgroups by tertiles: C3_quartile.L (0.39 to 0.80 g/L), C3_quartile.Q (0.81 to 0.94 g/L), and C3_quartile.C (0.95 to 1.63 g/L). The C3_quartile.Q was set as the baseline because it encompasses the inflection point (0.83 g/L) and thus represents the patient group with the lowest risk.

Seventeen parameters with p < 0.1 in univariate logistic regression were included in multivariate analysis (Figure 4). The high C3 tertile (C) was significantly associated with VC [odds ratio (OR) = 2.06, 95% confidence interval (CI): 1.13 to 3.83, p = 0.020], whereas the low tertile (L) showed no significant association. Despite a lower mean C3 in the VC group, the highest C3 tertile conferred a twofold VC risk (OR = 2.06). This apparent contradiction can be explained by the J-shaped relationship identified in the RCS analysis.

Despite a lower mean C3 in the VC group, the highest C3 tertile conferred a twofold VC risk (OR = 2.06). This apparent contradiction can be explained by the J-shaped relationship identified in the RCS analysis. The J-shaped curve indicates that both low and high levels of C3 are associated with an increased risk of VC, with the lowest risk occurring at an intermediate C3 level (0.81 to 0.94 g/L). Therefore, while the mean C3 level in the VC group is lower, the highest C3 tertile still represents a significant risk factor for VC.

Figure 4

Estimated odds ratios determined in a logistic regression model. OR, odds ratio; CI, confidence interval. Among 17 risk factors, only C3_quartileC, age, hypertension, and hyperlipidemia prevalence had a p-value <0.05.

Figure image at the original source: open the original paper. This file is not included in this text import.

In addition to C3, older age, hypertension, and hyperlipidemia were identified as independent risk factors for VC in NDD-CKD patients.

4.5

The predictive value of C3 for VC in NDD-CKD patients

The ROC curve was used to analyze the ability of C3 to diagnose vascular calcification, which showed an area under the curve (AUC) of 0.849 (95% confidence interval: 0.814 to 0.884) for C3 in predicting VC, indicating high diagnostic accuracy (Table 2).

Table 2

The predictive value of C3 for VC in NDD-CKD patients.

Cut-offSensitivitySpecificityAccuracyAUCAUC 95% CI
0.5340.7940.7670.7810.8490.849 (0.814 to 0.884)

AUC, area under the curve; CI, confidence interval; C3, complement3; VC, vascular calcification; NDD-CKD, non-dialysis dependent CKD.

4.6

Subgroup analysis by glomerulonephritis status

Given the distinct role of the complement system in GN pathophysiology, we conducted subgroup analyses to examine how the presence or absence of GN status affected the relationship between C3 and vascular calcification. We observed a significant positive association in patients with GN (OR = 6.01, p = 0.033). In contrast, the association in the non-GN subgroup did not reach statistical significance (OR = 0.018, p = 0.066).

Source: Results Source: Results Source: Results Source: Results Source: Results Source: Results

Conclusion

In patients with NDD-CKD, serum complement C3 exhibits a J-shaped relationship with vascular calcification, indicating a complex, non-linear association. Additionally, older age, hypertension, and hyperlipidemia were confirmed as independent risk factors.

Source: Conclusion
Authors’ abstract

Background

Previous studies have shown that complement activation is associated with an increased risk of cardiovascular disease in patients with chronic kidney disease (CKD) on dialysis. This study aims to investigate the relationship between complement 3 (C3) and vascular calcification (VC) in non-dialysis-dependent CKD (NDD-CKD) patients.

Methods

Four hundred and fifty six NDD-CKD patients were enrolled from 2019 to 2022. C3 was measured by immunoscattering turbidimetry. According to the results of CT imaging, the patients were divided into the aorta vascular calcification group and the non-aortic vascular calcification group. Restricted cubic spline (RCS) analysis and logistic regression model were used to explore the association between C3 and VC in NDD-CKD patients. To assess how it predicted, a receiver operating characteristic (ROC) analysis was undertaken.

Results

In NDD-CKD patients, the third tertile of C3 (0.95 to 1.63 g/L) was significantly correlated with VC (OR = 2.06, 95% CI: 1.13 to 3.83, p = 0.020). Older age and history of underlying diseases (hypertension, hyperlipidemia) are independent risk factors for VC in NDD-CKD patients. The area under the curve (AUC) of C3 for predicting VC was 0.849 g/L (sensitivity, 79.4%; specificity, 76.7%).

Conclusion

In patients with NDD-CKD, serum complement C3 exhibits a J-shaped relationship with vascular calcification, indicating a complex, non-linear association. Additionally, older age, hypertension, and hyperlipidemia were confirmed as independent risk factors.

Read the full paper
1

Introduction

Cardiovascular events represent the primary determinant of poor prognosis in patients with CKD (1 to 4). VC, highly prevalent in CKD populations, strongly predicts cardiovascular mortality (5 to 7). Despite the established significance of VC, the clinical tools for its robust evaluation in routine practice remain suboptimal. Traditional biomarkers, such as serum calcium, phosphate, and parathyroid hormone (PTH), have been extensively studied. However, their predictive performance for VC has consistently been modest and inconsistent across studies. Moreover, other novel biomarkers, such as fibroblast growth factor-23 (FGF-23) and klotho, while mechanistically involved, have yet to demonstrate sufficient prognostic value or cost-effectiveness to be adopted into widespread clinical practice (8, 9).

Recent studies have shown that complement activation is associated with many diseases and their complications (10). Nagaraj et al. (11) reported a significant correlation between higher C3 levels and the presence and severity of arterial calcification in healthy midlife women. Extending this concept to metabolic disease, Copenhaver et al. (12) demonstrated that elevated C3 and C4 levels in obese youth may serve as early indicators for atherosclerosis risk. Collectively, these findings position complement components as promising biomarkers for cardiovascular risk stratification (13).

This association has been confirmed in hemodialysis-dependent CKD (HD-CKD) patients, with C3 identified as an independent risk factor for VC (14). Nonetheless, the unique uremic milieu and intensive dialysis regimens in HD patients may confound the specific role of C3. Given the high incidence and progression of VC in NDD-CKD patients (15), reliance on HD data alone is insufficient for understanding this relationship at earlier, more modifiable disease stages. Thus, the utility of C3 as a VC biomarker in NDD-CKD patients remains an unaddressed gap.

This study aims to explore the relationship between C3 and VC in NDD-CKD patients, providing novel insights for the targeted precision therapy of VC.

2

Materials and methods

2.1

Study subjects

This cross-sectional observational study screened 737 NDD-CKD patients at Xuanwu Hospital of Capital Medical University from 2019 to 2022. Our exploration was restricted to subjects over 18 years old (N = 737). A series of sample selection processes were applied according to the exclusion criteria: (1) history of dialysis or kidney transplantation (N = 22); (2) patients with acute renal failure (N = 38); patients with active systemic inflammation or acute infection (N = 20); (3) autoimmune diseases (N = 6); (4) incomplete test for VC (N = 240); (5) missing data on available covariates: C3 (N = 8); C4 (N = 8); serum calcium (N = 13); uric acid (N = 253); 24 urinary protein (N = 46).

Consequently, our study included 456 adult participants with complete information in the final analysis (Figure 1). The participants provided written informed consent before enrollment, and research protocols were approved by the Ethics Committee of Xuanwu Hospital, Capital Medical University [(2019)131].

Figure 1

Flowchart of participants’ selection.

Figure image at the original source: open the original paper. This file is not included in this text import.
2.2

Study methods

Clinical data were collected from 456 NDD-CKD patients, including demographics (gender, age, smoking status, alcohol use), etiology, CKD stage, blood pressure (systolic/diastolic), and medical history (hypertension, diabetes, chronic heart disease, hyperlipidemia, calcium carbonate/vitamin D supplementation). Serum levels of calcium, phosphorus, albumin, hemoglobin, uric acid, total cholesterol, low-density lipoprotein cholesterol (LDL-C), creatinine, and alanine were measured using an automatic biochemical analyzer. The levels of C3 and complement 4 (C4) were quantified via immunoscattering turbidimetry.

2.3

Assessment of vascular calcification

Vascular calcification (VC) was assessed using available chest CT imaging. The thoracic aorta was evaluated. VC was defined as discrete foci of ≥1 mm2 within the aortic wall with an attenuation of >130 Hounsfield units (HU), consistent with established methodologies (16).

3

Statistics

Data were analyzed using R (Version 4.3.2). Normally distributed continuous variables were described using mean ± standard deviation (SD) and compared via Student’s t-test. Non-normally distributed quantitative data were represented as median (interquartile range) [M (P25: P75)] and analyzed using the Mann: Whitney U-test. The categorical variables were described through absolute or relative frequencies (%), which were compared using the chi-square test (p < 0.05 considered significant). Spearman correlation analysis was used for correlation analysis. Multivariate logistic regression was performed to explore relationships between the indicators and VC in NDD-CKD patients.

The predictive value of C3 concentration for VC was evaluated by the ROC curves. The nonlinear relationship between C3 and vascular calcification was assessed using restricted cubic splines.

4

Results

4.1

Comparison of clinical characteristics and laboratory indexes consisting of C3 and C4 levels in the group with and without VC

A total of 456 NDD-CKD patients were enrolled, including 233 with VC and 223 without VC. The general situation of the vascular calcification group and the non-vascular calcification group is presented in Table 1. The median age of the patients in the CKD with VC group was 65.00 (58.00 to 72.00) years. The median age of the patients in the CKD without VC group was 53.00 (42.00 to 64.00) years. By comparing patients with and without VC, the history of calcium carbonate or vitamin D supplementation showed no statistical difference (p > 0.05), whereas sex, smoking status, alcohol consumption, history of underlying diseases (hypertension, diabetes, chronic heart disease, hyperlipidemia), CKD stage, and cause of CKD were significantly associated with VC (p < 0.05).

Table 1

Comparison of baseline characteristics between those without VC and the VC groups in NDD-CKD patients.

VariablesCKD without VC group (N = 223)CKD with VC group (N = 233)p-value
Age [M (P25: P75), years]53.00 (42.00 to 64.00)65.00 (58.00 to 72.00)<0.001*
Sex0.007*
Male/[n (%)]128 (57.4%)164 (70.4%)
Female/[n (%)]95 (42.6%)69 (29.6%)
Smoking/[n (%)]90 (40.4%)132 (56.7%)<0.001*
Drinking/[n (%)]60 (26.9%)98 (42.1%)<0.001*
Underlying diseases<0.001*
Hypertension/[n (%)]166 (74.4%)212 (90.9%)
Diabetes/[n (%)]80 (35.9%)152 (65.2%)
CHD/[n (%)]28 (12.6%)73 (31.3%)
Hyperlipidemia/[n (%)]112 (50.2%)156 (67.0%)
History of medications
Calcium carbonate/[n (%)]72 (32.3%)60 (25.8%)0.140
Vitamin D/[n (%)]54 (24.2%)44 (18.9%)0.140
CKD stage<0.001*
CKD1/[n (%)]69 (30.9%)25 (10.7%)
CKD2/[n (%)]34 (15.2%)33 (14.2%)
CKD3/[n (%)]46 (20.6%)82 (35.2%)
CKD4/[n (%)]36 (11.7%)41 (17.6%)
CKD5/[n (%)]38 (17.0%)52 (22.3%)
Etiology of CKD<0.001*
DKD/[n (%)]41 (18.4%)88 (37.8%)
HRD/[n (%)]13 (5.83%)21 (9.01%)
Glomerulonephritis/[n (%)]169 (75.8%)124 (53.2%)
Serum phosphate (mean ± SD, mmol/L)1.29 ± 0.401.34 ± 0.360.019*
Serum calcium (mean ± SD, mmol/L)2.15 ± 0.212.16 ± 0.270.740
BMI (mean ± SD, kg/m2)26.38 ± 4.4426.16 ± 4.310.437
SBP (mean ± SD, mmHg)142.04 ± 21.08146.95 ± 21.170.011*
DBP (mean ± SD, mmHg)86.57 ± 15.2581.91 ± 11.93<0.004*
24urinary protein (mean ± SD, g/24 h)3.12 ± 2.732.95 ± 2.910.247
Creatinine (mean ± SD, μmol)229.37 ± 243.92263.06 ± 275.960.001*
Alanine (mean ± SD, IU/L)22.18 ± 16.5216.82 ± 9.95<0.001*
Cholesterol (mean ± SD, mmol/L)5.17 ± 2.074.64 ± 1.580.005*
Low-density lipoprotein (mean ± SD, mmol/L)3.19 ± 1.722.79 ± 1.200.019*
ALB (mean ± SD, g/L)33.77 ± 7.9733.50 ± 6.630.318
C3 (mean ± SD, g/L)0.91 ± 0.210.86 ± 0.200.011*
C4 (mean ± SD, g/L)0.25 ± 0.080.25 ± 0.080.841
Uric acid [M (P25: P75), μmol/L]401 (319 to 478.5)414 (340 to 501)0.062
Hemoglobin [M (P25: P75), g/L]109 (94.5 to 133)108 (93 to 119)0.015*

Data are shown as mean ± SD or median (interquartile range) for continuous variables and proportions for categorical variables. p < 0.05 is marked with *.

VC, vascular calcification; CKD, chronic kidney disease; CHD, chronic heart disease; HRD, hypertensive renal damage; DKD, diabetic kidney disease; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; ALB, albumin; VC, vascular calcification; CKD, chronic kidney disease; C3, complement 3; C4, complement 4.

The VC group exhibited higher systolic blood pressure, creatinine, and serum phosphate than those in the group without VC (p < 0.05), and lower diastolic blood pressure, cholesterol, low-density lipoprotein cholesterol, and hemoglobin than those in the group without VC (p < 0.05). Serum calcium, body mass index (BMI), 24-h urinary protein, and uric acid did not differ between the two groups (p > 0.05).

When analyzed as continuous variables, C3 showed a significant negative association with VC (p < 0.05), with a monotonic downward trend in the non-VC group, while C4 was not statistically significant.

4.2

Correlation between C3 and VC and laboratory indicators

Initial Spearman correlation analysis showed that C3 was negatively correlated with VC (r = −0.113, p = 0.015) and positively correlated with hemoglobin, alanine, cholesterol, and low-density lipoprotein cholesterol (ρ = 0.352, 0.264, 0.183, 0.163, p < 0.001) (see Figure 2).

Figure 2

Correlation between plasma C3 and hemoglobin in NDD-CKD patients. NDD-CKD, non-dialysis chronic kidney disease. Correlation between plasma C3 level and hemoglobin in NDD-CKD patients, Spearman’s ρ = 0.18, p < 0.001.

Figure image at the original source: open the original paper. This file is not included in this text import.
4.3

Nonlinear association between C3 and traditional VC risk factors

Given the complex biology of the complement system, we further used restricted cubic spline (RCS) curve analysis to explore possible nonlinear relationships between C3 and VC. The RCS analysis confirmed a J-shaped relationship between C3 and VC (p = 0.045), with an inflection point at 0.83 g/L. Below or above this value, the risk of VC increased (Figure 3).

Figure 3

Nonlinear association between C3 and vascular calcification. VC, vascular calcification. Restricted cubic spline analysis revealed a significant non-linear J-shaped association between C3 levels and vascular calcification risk (p-non-linear <0.001), with overall statistical significance (p-overall = 0.045).

Figure image at the original source: open the original paper. This file is not included in this text import.
4.4

Analysis of influencing factors of VC in NDD-CKD patients

The J-shaped relationship clarifies that the risk of VC is not uniformly related to C3 across its entire range, and the mean value may mask the true relationship. To further investigate this, C3 was divided into three subgroups by tertiles: C3_quartile.L (0.39 to 0.80 g/L), C3_quartile.Q (0.81 to 0.94 g/L), and C3_quartile.C (0.95 to 1.63 g/L). The C3_quartile.Q was set as the baseline because it encompasses the inflection point (0.83 g/L) and thus represents the patient group with the lowest risk.

Seventeen parameters with p < 0.1 in univariate logistic regression were included in multivariate analysis (Figure 4). The high C3 tertile (C) was significantly associated with VC [odds ratio (OR) = 2.06, 95% confidence interval (CI): 1.13 to 3.83, p = 0.020], whereas the low tertile (L) showed no significant association. Despite a lower mean C3 in the VC group, the highest C3 tertile conferred a twofold VC risk (OR = 2.06). This apparent contradiction can be explained by the J-shaped relationship identified in the RCS analysis.

Despite a lower mean C3 in the VC group, the highest C3 tertile conferred a twofold VC risk (OR = 2.06). This apparent contradiction can be explained by the J-shaped relationship identified in the RCS analysis. The J-shaped curve indicates that both low and high levels of C3 are associated with an increased risk of VC, with the lowest risk occurring at an intermediate C3 level (0.81 to 0.94 g/L). Therefore, while the mean C3 level in the VC group is lower, the highest C3 tertile still represents a significant risk factor for VC.

Figure 4

Estimated odds ratios determined in a logistic regression model. OR, odds ratio; CI, confidence interval. Among 17 risk factors, only C3_quartileC, age, hypertension, and hyperlipidemia prevalence had a p-value <0.05.

Figure image at the original source: open the original paper. This file is not included in this text import.

In addition to C3, older age, hypertension, and hyperlipidemia were identified as independent risk factors for VC in NDD-CKD patients.

4.5

The predictive value of C3 for VC in NDD-CKD patients

The ROC curve was used to analyze the ability of C3 to diagnose vascular calcification, which showed an area under the curve (AUC) of 0.849 (95% confidence interval: 0.814 to 0.884) for C3 in predicting VC, indicating high diagnostic accuracy (Table 2).

Table 2

The predictive value of C3 for VC in NDD-CKD patients.

Cut-offSensitivitySpecificityAccuracyAUCAUC 95% CI
0.5340.7940.7670.7810.8490.849 (0.814 to 0.884)

AUC, area under the curve; CI, confidence interval; C3, complement3; VC, vascular calcification; NDD-CKD, non-dialysis dependent CKD.

4.6

Subgroup analysis by glomerulonephritis status

Given the distinct role of the complement system in GN pathophysiology, we conducted subgroup analyses to examine how the presence or absence of GN status affected the relationship between C3 and vascular calcification. We observed a significant positive association in patients with GN (OR = 6.01, p = 0.033). In contrast, the association in the non-GN subgroup did not reach statistical significance (OR = 0.018, p = 0.066).

5

Discussion

This study provides the first exploration of the association between C3 and VC in patients with NDD-CKD. Our findings reveal a significant J-shaped relationship (p = 0.045), with an inflection point at 0.83 g/L. This indicates that both low and high C3 levels are associated with an increased risk of VC, revealing a previously unrecognized complexity in their association.

Previous studies have demonstrated that the complement system may play a crucial role in the development of VC (17). A study in subclinical atherosclerosis has identified complement system activation as a hallmark of early plaque formation (18). Complement C3 is the core of the complement system, with the highest serum content in all complement components, and is the intersection hub of complement activation pathways (19). In hemodialysis patients, Wang et al. (14) have demonstrated that C3 acts as a predictor of vascular calcification.

Our study also confirmed the association of C3 and vascular calcification in non-hemodialysis patients. However, unlike the linear relationship between C3 and VC in hemodialysis patients (14), a J-shaped relationship was observed in NDD-CKD patients in our study. This difference may be attributed to complement activation’s involvement in hypersensitivity reactions (such as CARPA) and acute reactions during HD. The uremic environment and recurrent inflammatory stimuli during dialysis may significantly alter C3 metabolism compared to the non-dialysis state (20).

The J-shaped relationship demonstrates that the apparent paradox, a lower mean C3 level in the VC group alongside an elevated risk in the highest C3 tertile, arises because the population mean obscures a high-risk subgroup driven by elevated C3 levels. Similar to bone formation, vascular calcification is a process of ectopic bone formation influenced by factors like abnormal mineral metabolism, uremic toxins, inflammation, and oxidative stress (21, 22). On one hand, complement C3 has a dual role in inducing osteoclast formation (23) and regulating the inflammatory environment, impacting osteoclast differentiation (24).

This enhanced osteoclast activity can lead to bone loss, increasing blood calcium levels, and the risk of soft tissue calcification in vascular walls, which may promote vascular calcification (25, 26). On the other hand, our study showed that low complement C3 levels also caused vascular calcification. The complement system is not only involved in the inflammatory response, but also in the removal of cellular debris and apoptotic cells (10). We propose that low C3 levels may result in impaired clearance of these functions, allowing cell debris and apoptotic cells to accumulate in the vessel wall.

This accumulated cellular debris can act as an inducer of calcification and promote the formation of hydroxyapatite crystals, which can lead to vascular calcification (27). In addition to low C3 levels, an imbalance in complement regulation, potentially caused by excessive activation, could be a significant factor. This idea is supported by the predictive value of the C3d/C3 ratio, which reflects the balance between activation and abundance (28). Studies have shown that deficiencies in regulators like CD59 can worsen vascular disease (29).

To better understand the role of complement dysregulation in vascular calcification, future research should focus on quantifying complement activation fragments and regulators directly. While our study highlights the importance of complement dysregulation, it is essential to recognize that vascular calcification is a complex process involving multiple factors, including the FGF-23: Klotho axis and oxidative stress (30 to 32). Future prospective studies should measure these factors in conjunction with complement components to better understand their interactions and contributions to VC.

Clinically, NDD-CKD patients with VC were significantly older than patients without VC (65 years vs. 53 years), had higher systolic blood pressure, lower diastolic blood pressure, cholesterol, low-density lipoprotein, and hemoglobin, and higher rates of hypertension, diabetes, and hyperlipidemia prevalence (all p < 0.05), showing no difference in calcium/vitamin D supplementation. This is generally consistent with prior studies (33 to 35). Meanwhile, in this study, C3 was found to be positively correlated with hemoglobin, total cholesterol, and LDL-C, markers of inflammatory responses and metabolic disorders (36).

Inflammation and metabolic disorders are important risk factors for VC, suggesting indirect VC promotion via these pathways, while this study did not demonstrate a significant relationship between C4 and VC, aligning with studies in hemodialysis patients. However, Bi et al. (37) identified C4 as a prognostic marker in IgA nephropathy patients. This study did not include prognostic analysis due to the short follow-up time, but future studies should explore the association of plasma C4 levels with cardiovascular disease (CVD) and mortality in NDD-CKD patients.

The impact of C3 activation on vascular calcification (VC) may vary depending on the underlying etiology of kidney disease, as complement dysregulation is a common feature in various glomerulonephritides, including IgA nephropathy, lupus nephritis, APS, and others, as documented in previous studies (38, 39). This diversity in etiology prompted us to stratify our analysis by glomerulonephritis (GN) status. Our analysis demonstrated a significant association between higher C3 levels and an increased risk of VC in the GN subgroup.

However, in the non-GN subgroup, this association did not reach statistical significance, likely due to the limited statistical power of the smaller cohort (approximately 100 patients). Future large-scale, multicenter studies with etiology-specific designs are needed to validate these potential differences and elucidate the underlying pathophysiology.

The ROC curve showed that the AUC of C3 in predicting VC in NDD-CKD patients was 0.849 g/L, indicating a high predictive value. The predictive sensitivity and specificity were 79.4 and 76.7%, respectively. C3 may be an important biomarker for predicting VC in NDD-CKD patients.

In clinical practice, C3 serves as a valuable biomarker for assessing the risk of vascular calcification in patients with NDD-CKD. In patients with markedly altered C3 levels, whether elevated or decreased, especially among the elderly with hypertension and hyperlipidemia, close monitoring for signs of VC (using methods such as X-ray) is essential for the early identification of high-risk individuals. In addition to monitoring, the trend in C3 levels can guide clinical management decisions. Elevated C3 levels, particularly those in the high-normal range, may require closer monitoring, whereas low C3 levels may indicate complement dysregulation or associated comorbidities.

This targeted approach facilitates more precise interventions, ultimately improving patient outcomes.

This study has several limitations that should be considered when interpreting the findings. First, we could only classify vascular calcification as present or absent due to the lack of a standardized grading system for aortic calcification on CT scans. While our method was reliable, it may not fully capture the range of disease severity. Second, a single cross-sectional C3 measurement may not accurately reflect long-term complement dynamics, though we mitigated this by excluding patients with acute comorbidities known to cause transient fluctuations.

Additionally, medication use was documented from medical records, but real-world adherence may not have been fully captured. Finally, as a single-center study, our findings require validation in more diverse populations. Despite these limitations, the consistency and robustness of the primary nonlinear association provide compelling evidence for a complex relationship between C3 and vascular calcification, laying the groundwork for future longitudinal studies with quantitative calcification scoring.

Collectively, these findings deepen our understanding of the possible mechanisms of VC. With the ongoing development of C3-targeted therapies, in the future, C3 may be applied to the clinical treatment of VC in CKD, thereby improving the quality of life for patients and achieving better survival benefits.

6

Conclusion

In patients with NDD-CKD, serum complement C3 exhibits a J-shaped relationship with vascular calcification, indicating a complex, non-linear association. Additionally, older age, hypertension, and hyperlipidemia were confirmed as independent risk factors.

Acknowledgments

The invaluable support of all staff of the Department of Nephrology, Xuanwu Hospital, Capital Medical University, is gratefully acknowledged.

Edited by: Bogdan Timar, Victor Babes University of Medicine and Pharmacy, Romania

Reviewed by: Qi Feng Liu, First People’s Hospital of Kunshan, China

Khaled Mohamed Amin Elzorkany, King Faisal University, Saudi Arabia

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving humans were conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of Xuanwu Hospital, Capital Medical University [(2019) 131]. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.

Author contributions

CF: Data curation, Writing: original draft, Writing: review & editing. WL: Data curation, Writing: review & editing. WX: Data curation, Writing: review & editing. XH: Data curation, Writing: review & editing. WC: Data curation, Writing: review & editing. AZ: Conceptualization, Funding acquisition, Writing: review & editing.

Conflict of interest

The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declared that Generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Zoccali C Mallamaci F Adamczak M de Oliveira RB Massy ZA Sarafidis P . Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association . Cardiovasc Res . (2023 ) 119 :2017Not reported32 . doi: 10.1093/cvr/cvad083 , 37249051 PMC10478756
2. Cai H Lu R Zhang M Pang H Zhu M Zhang W . Serum soluble Klotho level is associated with abdominal aortic calcification in patients on maintenance hemodialysis . Blood Purif . (2015 ) 40 :120Not reported6 . doi: 10.1159/000381937 , 26159932
3. Wang X-R Zhang J-J Xu X-X Wu Y-G . Prevalence of coronary artery calcification and its association with mortality, cardiovascular events in patients with chronic kidney disease: a systematic review and meta-analysis . Ren Fail . (2019 ) 41 :244Not reported56 . doi: 10.1080/0886022X.2019.1595646 , 31014155 PMC6493287
4. Jung C-Y Yun H-R Park JT Joo YS Kim HW Yoo T-H . Association of coronary artery calcium with adverse cardiovascular outcomes and death in patients with chronic kidney disease: results from the KNOW-CKD . Nephrol Dial Transplant . (2023 ) 38 :712Not reported21 . doi: 10.1093/ndt/gfac194 , 35689669
5. Fang Y Ginsberg C Sugatani T Monier-Faugere M-C Malluche H Hruska KA . Early chronic kidney disease-mineral bone disorder stimulates vascular calcification . Kidney Int . (2014 ) 85 :142Not reported50 . doi: 10.1038/ki.2013.271 , 23884339 PMC3836911
6. Cano-Megías M Guisado-Vasco P Bouarich H de Arriba-de la Fuente G de Sequera-Ortiz P Álvarez-Sanz C . Coronary calcification as a predictor of cardiovascular mortality in advanced chronic kidney disease: a prospective long-term follow-up study . BMC Nephrol . (2019 ) 20 :188 . doi: 10.1186/s12882-019-1367-1 , 31138150 PMC6537175
7. Zhang H Li G Yu X Yang J Jiang A Cheng H . Progression of vascular calcification and clinical outcomes in patients receiving maintenance dialysis . JAMA Netw Open . (2023 ) 6 :e2310909 . doi: 10.1001/jamanetworkopen.2023.10909 , 37126347 PMC10152309
8. Yang K Yang J Bi X Yu Z Xiao T Huang Y . Serum Klotho, cardiovascular events, and mortality in nondiabetic chronic kidney disease . Cardiorenal Med . (2020 ) 10 :175Not reported87 . doi: 10.1159/000506380 , 32294646
9. Yu L-X Liu Q-F Feng J-H Li S-S Gu X-X Xiong Y . Association of soluble Klotho level with adverse outcomes in patients on maintenance hemodialysis . Dis Markers . (2020 ) 2020 :4923970 . doi: 10.1155/2020/4923970 , 33299496 PMC7708020
10. Liu A Luo P Huang H . New insight of complement system in the process of vascular calcification . J Cell Mol Med . (2023 ) 27 :1168Not reported78 . doi: 10.1111/jcmm.17732 , 37002701 PMC10148053
11. Nagaraj N Matthews KA Shields KJ Barinas-Mitchell E Budoff MJ El Khoudary SR . Complement proteins and arterial calcification in middle aged women: cross-sectional effect of cardiovascular fat. The SWAN Cardiovascular Fat Ancillary Study . Atherosclerosis . (2015 ) 243 :533Not reported9 . doi: 10.1016/j.atherosclerosis.2015.10.095 , 26523990 PMC4817718
12. Copenhaver MM Yu C-Y Zhou D Hoffman RP . Relationships of complement components C3 and C4 and their genetics to cardiometabolic risk in healthy, non-Hispanic white adolescents . Pediatr Res . (2020 ) 87 :88Not reported94 . doi: 10.1038/s41390-019-0534-1 , 31404919 PMC6962538
13. Nilsson B Hamad OA Ahlström H Kullberg J Johansson L Lindhagen L . C3 and C4 are strongly related to adipose tissue variables and cardiovascular risk factors . Eur J Clin Investig . (2014 ) 44 :587Not reported96 . doi: 10.1111/eci.12275 , 24754458
14. Wang Y Miao Y Gong K Cheng X Chen Y Zhao M-H . Plasma complement protein C3a level was associated with abdominal aortic calcification in patients on hemodialysis . J Cardiovasc Transl Res . (2019 ) 12 :496Not reported505 . doi: 10.1007/s12265-019-09885-2 , 30989586
15. Bover J Aguilar A Arana C Molina P Lloret MJ Ochoa J . Clinical approach to vascular calcification in patients with non-dialysis dependent chronic kidney disease: mineral-bone disorder-related aspects . Front Med . (2021 ) 8 :642718 . doi: 10.3389/fmed.2021.642718 , 34095165 PMC8171667
16. Cao L Ma L Ma T Sun G Niu Z Zhang H . Determinants of thoracic aortic calcification and its effects on thoracic aortic size . Int J Cardiovasc Imaging . (2025 ) 41 :1767Not reported77 . doi: 10.1007/s10554-025-03481-z , 40742633
17. Matsuoka K Park K-A Ito M Ikeda K Takeshita S . Osteoclast-derived complement component 3a stimulates osteoblast differentiation . J Bone Miner Res . (2014 ) 29 :1522Not reported30 . doi: 10.1002/jbmr.2187 , 24470120
18. Martínez-López D Roldan-Montero R García-Marqués F Nuñez E Jorge I Camafeita E . Complement C5 protein as a marker of subclinical atherosclerosis . J Am Coll Cardiol . (2020 ) 75 :1926Not reported41 . doi: 10.1016/j.jacc.2020.02.058 , 32327104
19. Ling M Murali M . Analysis of the complement system in the clinical immunology laboratory . Clin Lab Med . (2019 ) 39 :579Not reported90 . doi: 10.1016/j.cll.2019.07.006 31668271
20. Pethő ÁG Révész C Mészáros T Sáfár O Rosivall L Domán J . Pathophysiological changes in patients during hemodialysis and blood reinfusion predict potential development of hemodialysis reactions . Ren Fail . (2025 ) 47 :2500662 . doi: 10.1080/0886022X.2025.2500662 , 40328739 PMC12057777
21. Wang X-R Yuan L Shi R Li H Wang D-G Wu Y-G . Predictors of coronary artery calcification and its association with cardiovascular events in patients with chronic kidney disease . Ren Fail . (2021 ) 43 :1172Not reported9 . doi: 10.1080/0886022X.2021.1953529 , 34315328 PMC8330733
22. Mill C George SJ . Wnt signalling in smooth muscle cells and its role in cardiovascular disorders . Cardiovasc Res . (2012 ) 95 :233Not reported40 . doi: 10.1093/cvr/cvs141 , 22492675
23. Ren F Zheng S Luo H Yu X Li X Song S . Fibroblast derived C3 promotes the progression of experimental periodontitis through macrophage M1 polarization and osteoclast differentiation . Int J Oral Sci . (2025 ) 17 :30 . doi: 10.1038/s41368-025-00361-z , 40240339 PMC12003657
24. Jang D-I Lee AH Shin H-Y Song H-R Park J-H Kang T-B . The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics . Int J Mol Sci . (2021 ) 22 :2719 . doi: 10.3390/ijms22052719 , 33800290 PMC7962638
25. Wang Z-X Luo Z-W Li F-X-Z Cao J Rao S-S Liu Y-W . Aged bone matrix-derived extracellular vesicles as a messenger for calcification paradox . Nat Commun . (2022 ) 13 :1453 . doi: 10.1038/s41467-022-29191-x , 35304471 PMC8933454
26. Cannata-Andia JB Roman-Garcia P Hruska K . The connections between vascular calcification and bone health . Nephrol Dial Transplant . (2011 ) 26 :3429Not reported36 . doi: 10.1093/ndt/gfr591 , 22039012 PMC4176055
27. Liu Q Luo Y Zhao Y Xiang P Zhu J Jing W . Nano-hydroxyapatite accelerates vascular calcification via lysosome impairment and autophagy dysfunction in smooth muscle cells . Bioact Mater . (2021 ) 8 :478Not reported93 . doi: 10.1016/j.bioactmat.2021.06.004 , 34541414 PMC8429627
28. Poppelaars F da Gaya Costa M Faria B Berger SP Assa S Daha MR . Intradialytic complement activation precedes the development of cardiovascular events in hemodialysis patients . Front Immunol . (2018 ) 9 :2070 . doi: 10.3389/fimmu.2018.02070 , 30271407 PMC6146103
29. Vaisar T Durbin-Johnson B Whitlock K Babenko I Mehrotra R Rocke DM . Urine complement proteins and the risk of kidney disease progression and mortality in type 2 diabetes . Diabetes Care . (2018 ) 41 :2361Not reported9 . doi: 10.2337/dc18-0699 , 30150236 PMC6196831
30. Wungu CDK Susilo H Alsagaff MY Witarto BS Witarto AP Pakpahan C . Role of klotho and fibroblast growth factor 23 in arterial calcification, thickness, and stiffness: a meta-analysis of observational studies . Sci Rep . (2024 ) 14 :5712 . doi: 10.1038/s41598-024-56377-8 , 38459119 PMC10923819
31. Chen Y-X Huang C Duan Z-B Xu C-Y Chen Y . Klotho/FGF23 axis mediates high phosphate-induced vascular calcification in vascular smooth muscle cells via Wnt7b/β-catenin pathway . Kaohsiung J Med Sci . (2019 ) 35 :393Not reported400 . doi: 10.1002/kjm2.12072 , 31001900 PMC11900703
32. Kuro-O M . The Klotho proteins in health and disease . Nat Rev Nephrol . (2019 ) 15 :27Not reported44 . doi: 10.1038/s41581-018-0078-3 , 30455427
33. Onuma OK Pencina K Qazi S Massaro JM D’Agostino RB Chuang ML . Relation of risk factors and abdominal aortic calcium to progression of coronary artery calcium (from the Framingham Heart Study) . Am J Cardiol . (2017 ) 119 :1584Not reported9 . doi: 10.1016/j.amjcard.2017.02.021 , 28442125 PMC5734670
34. Cozzolino M Ciceri P Galassi A Mangano M Carugo S Capelli I . The key role of phosphate on vascular calcification . Toxins . (2019 ) 11 :213 . doi: 10.3390/toxins11040213 , 30970562 PMC6521180
35. Yang J Lee K-B Kim H Kim SW Kim YH Sung SA . Statin use and the progression of coronary artery calcification in CKD: findings from the KNOW-CKD study . Kidney Int Rep . (2024 ) 9 :3027Not reported34 . doi: 10.1016/j.ekir.2024.07.033 , 39430188 PMC11489501
36. Xin Y Hertle E van der Kallen CJH Vogelzangs N Arts ICW Schalkwijk CG . C3 and alternative pathway components are associated with an adverse lipoprotein subclass profile: the CODAM study . J Clin Lipidol . (2021 ) 15 :311Not reported9 . doi: 10.1016/j.jacl.2021.01.011 , 33612457
37. Bi T-D Zheng J-N Zhang J-X Yang L-S Liu N Yao L . Serum complement C4 is an important prognostic factor for IgA nephropathy: a retrospective study . BMC Nephrol . (2019 ) 20 :244 . doi: 10.1186/s12882-019-1420-0 , 31272400 PMC6610919
38. James MT Hemmelgarn BR Tonelli M . Early recognition and prevention of chronic kidney disease . Lancet . (2010 ) 375 :1296Not reported309 . doi: 10.1016/S0140-6736(09)62004-3 , 20382326
39. Vivarelli M Barratt J Beck LH Fakhouri F Gale DP Goicoechea de Jorge E . The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference . Kidney Int . (2024 ) 106 :369Not reported91 . doi: 10.1016/j.kint.2024.05.015 , 38844295
Publication and source details

Original title: Correlation between complement C3 level and abdominal aortic calcification in non-dialysis chronic kidney disease patients: a cross-sectional study

Chenfei Fu; Wen Li; Weijia Xu; Xinmei Huang; Wenqiong Cao; Aihua Zhang

Frontiers in Medicine · 2026

* Correspondence: Aihua Zhang, rosezhang998@hotmail.comCopyright © 2026 Fu, Li, Xu, Huang, Cao and Zhang.2026Fu, Li, Xu, Huang, Cao and Zhanghttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. National Natural Science Foundation of China10.13039/501100001809 8187361982370722The author(s) declared that financial support was received for this work and/or its publication. This research was funded by the National Natural Science Foundation of China, Grant Numbers 82370722 and 81873619; the Huizhi Talents Leading Cultivation Program of Xuanwu Hospital of Capital Medical University to AZ.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T00:11:32.391882+00:00

DOI: 10.3389/fmed.2026.1670422 · PMC12907140